Testing T-1301 capsules for advanced solid tumors
A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1301 Capsules in Subjects with Advanced Solid Tumors
This study is testing a new oral medication called T-1301 to see if it is safe and effective for people with advanced solid tumors, including lymphoma.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Taivex Therapeutics Corporation Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 3 sites (Kaohsiung City and 2 other locations) |
| Trial ID | NCT05156203 on ClinicalTrials.gov |
What this trial studies
This Phase 1 clinical trial evaluates the safety and tolerability of T-1301, a novel small-molecule inhibitor, in patients with advanced solid tumors, including lymphoma. The study is designed as an open-label, multi-center, dose-escalation trial to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). Approximately 30 patients will be enrolled, and T-1301 will be administered orally in a 28-day cycle, with treatment adjustments based on patient response and safety. The trial aims to gather critical pharmacokinetic data and assess the drug's efficacy in a population with limited treatment options.
Who should consider this trial
Good fit: Ideal candidates include adults aged 20 and older with advanced solid tumors or lymphoma that are refractory to standard treatments.
Not a fit: Patients with early-stage tumors or those who are eligible for standard treatment options may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors who have exhausted standard treatment options.
How similar studies have performed: While this approach is novel, similar studies involving kinase inhibitors have shown promise in treating advanced cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Having signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study.
2. Subjects with histologically and cytologically confirmed advanced solid tumors (including lymphoma) that are refractory to standard treatments, or for whom no standard treatment is available, or who are not amenable or unwilling to receive standard treatments.
3. Solid tumors that are measurable or evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy.
4. Have a life expectancy of ≥ 3 months in the Investigator's opinion.
5. Females or males ≥ 20 years old.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Recovered from prior treatment-related toxicity to at least grade 1 with the exception of alopecia.
8. Adequate organ function as defined by the following criteria:
1. Serum alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN)
2. Total serum bilirubin ≤ 1.5 x ULN
3. Absolute neutrophil count (ANC) ≥ 1500/µL
4. Platelets ≥ 100,000/µL
5. Hemoglobin ≥ 9.0 g/dL
6. Creatinine clearance (CrCl) ≥ 50 mL/min CrCl = \[(140 - age (year)) x weight (kg)\] / (serum creatinine x 72) (x 0.85 for females)
9. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
Exclusion Criteria:
1. Major surgery within 4 weeks prior to the first dose of study drug.
2. Subjects receiving any of the following anti-cancer therapy:
1. Anti-cancer definitive radiation therapy (4,000-6,000 cGy) within 4 weeks prior to the first dose of study drug.
2. Palliative radiation (≤ 10 fractions with total dose \< 3,000 cGy) within 2 weeks prior to the first dose of study drug.
3. Any systemic cytotoxic chemotherapy within 4 weeks prior to the first dose of study drug.
4. Any targeted therapy within 2 weeks or 5 half-lives, whichever is longer, prior to the first dose of study drug.
5. Any immunotherapy within 4 weeks prior to the first dose of study drug.
3. Any interventional treatments in another clinical trial following Exclusion Criteria 2c, 2d and 2e.
4. Subjects received blood transfusion or biological response modifiers (e.g., G-CSF) within 2 weeks prior to the first dose of study drug.
5. Subject who received autologous bone marrow transplant or stem cells rescue within 6 months prior to the first dose of study drug.
6. Subjects received strong inhibitors and/or inducers of CYP3A4 within 14 days prior to the first dose of study drug. A list of CYP3A4 modulators is provided in Appendix 3.
7. Documented or suspected brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.
8. Any of the following within 6 months of the first dose of study drug: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
9. Ongoing cardiac dysrhythmias of ≥ NCI CTCAE version 5.0 grade 2, or atrial fibrillation of any grade. Corrected QT interval by Fridericia (QTcF) ≥ 470 msec.
10. Hypertension that cannot be controlled by medications (\> 160/100 mm-Hg despite optimal medical therapy).
11. AIDS-defining opportunistic infections within the past 12 months.
12. Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV (anti-hepatitis C virus) antibody), unless the HCV RNA level is below the limit of detection (for subjects with positive anti-HCV Ab).
13. Men and women of childbearing potential who are unwilling to use highly effective contraceptive methods during the study period.
Highly effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.
14. If females, patient is pregnant or breast feeding.
15. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the investigator and/or sponsor, excess risk associated with study participation or study drug administration.
Where this trial is running
Kaohsiung City and 2 other locations
- Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City, Taiwan (Recruiting)
- Taipei Veterans General Hospital — Taipei, Taiwan (Recruiting)
- ChangGung Memorial Hospital, Linkou — Taoyuan City, Taiwan (Recruiting)
Study contacts
- Study coordinator: I-Fang Lee
- Email: iflee@taivex.com
- Phone: +886-2-2748-6200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.